We at Daiichi Sankyo are committed to providing patients with innovative treatment options which allow them to lead active and fulfilling lives. We focus on complex diseases that affect many people in Europe such as high blood pressure. We support the disease management with a strong portfolio of medicines1 for hypertension, dyslipidemia, bacterial infections and thrombotic disorders.
In Europe, four million people are dying of cardiovascular diseases every year2. Medication, that effectively treat the affected cardiovascular system, are highly needed.
Anticoagulation is of importance for the management and prevention of thromboembolic diseases, such as atrial fibrillation (AF) and venous thromboembolism (VTE). Our newest compound in Europe is Edoxaban1, a once-daily, oral anticoagulant. The European Committee (EC) granted marketing authorization for Edoxaban in June 2015.
Olmesartan1 is our product for hypertension. More than 5 million patients worldwide have been treated with this drug since 2002. Healthcare professionals around the world are demonstrating huge acceptance of olmesartan. It has achieved this success as a result of its excellent efficacy in lowering blood pressure. In Europe there are a range of single pills available powered by olmesartan from mono to triple combinations.
Our oral antiplatelet agent prasugrel1 helps to keep blood platelets from clotting together and developing a blockage in arteries in patients who had an acute coronary syndrome (ACS) and underwent a percutaneous coronary intervention (PCI).
|LIXIANA||Edoxaban||Anticoagulation. Approved in Europe for:|
|- prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ? 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA)|
|- treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults|
|Efient||Prasugrel||Acute coronary syndrome requiring percutaneous coronary intervention|
|Olmetec Plus||Olmesartan + Hydrochlorotiazide||Essential Hypertension|
|Sevikar||Olmesartan + Amlodipine||Essential Hypertension|
|Sevikar HCT||Olmesartan + Amlodipine + Hydrochlorothiazide||Essential Hypertension|
|Podomexef||Cefpodoxim||Respiratory tract infections|
1 For legal reasons detailed information about prescription medicine may only be given to healthcare professionals.
2 European Cardiovascular Disease Statistics 2012 by the European Heart Network